10/09 - Arts > Performance: Global Drum Project
10/11 - Arts > Performance: Cesaria Evora
10/12 - Arts > Exhibits: Between Earth and Heaven (last day)
10/14 - Arts > Performance: Druid Theatre Company
10/18 - Sports: Football vs. Stanford
By Kim Irwin

Dr. Owen Witte
Researchers at UCLA's Jonsson Comprehensive Cancer Center have modified a common chemotherapy drug to create a new probe for positron emission tomography (PET), an advance that will allow them to model and measure the immune system in action and monitor its response to new therapies.
The discovery, published June 8 in the early online edition of the peer-reviewed journal Nature Medicine, enables scientists to monitor the immune system three-dimensionally — at the whole-body level — as it tries to fight some cancers, or when it goes awry, as it does in autoimmune diseases.

Dr. Caius Radu
Researchers created a small molecule, called FAC, by slightly altering the molecular structure of one of the most commonly used chemotherapy drugs, gemcitabine. They then added a radiolabel so the cells that take in the probe can be seen during PET scanning.
Read the complete story at UCLA Today.
Published Jun 9, 2008 12:07 PM